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Abstract. Ribosomal RNA (rRNA) expression, one of the most 
important factors regulating ribosome production, is primarily 
controlled by a CG-rich 45S rDNA promoter. However, the 
DNA methylation state of the 45S rDNA promoter, as well 
as its effect on rRNA gene expression in types of human 
cancers is controversial. In the present study we analyzed the 
methylation status of the rDNA promoter (-380 to +53 bp) as 
well as associated rRNA expression levels in breast cancer cell 
lines and breast tumor-normal tissue pairs. We found that the 
aforementioned regulatory region was extensively methylated 
(74-96%) in all cell lines and in 68% (13/19 tumor-normal 
pairs) of the tumors. Expression levels of rRNA transcripts 
18S, 28S, 5.8S and 45S external transcribed spacer (45S ETS) 
greatly varied in the breast cancer cell lines regardless of their 
methylation status. Analyses of rRNA transcript expression 
levels in the breast tumor and normal matched tissues showed 
no significant difference when normalized with TBP. On the 
other hand, using the geometric mean of the rRNA expression 
values (GM-rRNA) as reference enabled us to identify signifi-
cant changes in the relative expression of rRNAs in the tissue 
samples. We propose GM-rRNA normalization as a novel 
strategy to analyze expression differences between rRNA 
transcripts. Accordingly, the 18S rRNA/GM-rRNA ratio 
was significantly higher whereas the 5.8S rRNA/GM-rRNA 
ratio was significantly lower in breast tumor samples than 
this ratio in the matched normal samples. Moreover, the 18S 
rRNA/GM-rRNA ratio was negatively correlated with the 45S 
rDNA promoter methylation level in the normal breast tissue 
samples, yet not in the breast tumors. Significant correlations 
observed between the expression levels of rRNA transcripts 
in the normal samples were lost in the tumor samples. We 
showed that the expression of rRNA transcripts may not be 
based solely on promoter methylation. Carcinogenesis may 
cause dysregulation of the correlation between spliced rRNA 
expression levels, possibly due to changes in rRNA processing, 
which requires further investigation.
Introduction
Breast cancer, the most common type of cancer among women, 
was also the primary and secondary cause of cancer-related 
deaths among women living in less developed (14.3% of all 
cancer-related deaths) and more developed regions (15.4% 
after lung cancer) in 2012, respectively (1). Familial or somatic 
mutations of BRCA1, BRCA2 and TP53 (alias p53) are well-
known high risk factors for breast cancer formation while 
others (PALB2, BRIP1, ATM, CHEK2, PTEN and CDH1) 
have been estimated to have moderate or weak effects (2).
Contrary to mutations that modify the DNA sequence 
itself, epigenetic alterations affect gene expression via DNA 
methylation, histone modifications and chromatin remod-
eling. DNA methylation, the frequently studied epigenetic 
modification in the context of embryogenesis, X chromosome 
inactivation and imprinting (3-5), is also important for the 
protection of genome integrity and hence cancer. Global hypo-
methylation of the genome, commonly observed in multiple 
cancers, increases genome instability and activates proto-
oncogenes while hypermethylation of promoter CpG islands 
silences the expression of tumor suppressor genes (6-8). 
Promoter DNA methylation, identified at the promoter region 
of many genes, contributes to breast tumorigenesis; however, 
DNA methylation of the rDNA region has been overlooked in 
DNA methylation studies related to breast cancer.
Ribosome synthesis is closely related to the cell metabo-
lism involved in cell growth and proliferation, and is tightly 
correlated with ribosomal RNA (rRNA) synthesis (9). The 
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human genome contains ~300-400 copies of rRNA genes 
but only a fraction of these genes are actively transcribed 
depending on the cell type, external signals and the cell stage, 
while the rest of the genes remain inactive (10). rRNA genes 
are organized in tandem repeated arrays within nucleolar 
organizing regions (NORs) located on the short arms of five 
human acrocentric chromosomes: chromosome 13, 14, 15, 
21 and 22 (11). rRNA genes (except 5S, which is transcribed 
by RNA polymerase III) are transcribed from the 45S rDNA 
promoter by RNA polymerase I (Pol I). Since ~60% of the 
total RNA of a cell consists of Pol I products (12), rRNA 
genes are regulated tightly at different levels that include 
pre-initiation complex (PIC) formation, initiation, promoter 
escape, elongation, termination, re-initiation, RNA processing 
and post-transcriptional modifications (13).
The entire promoter region of rRNA genes is contained 
in an intergenic spacer region (IGS) between rDNA units. 
The promoter region of rDNA repeating unit consists of 
two important elements: the core promoter and upstream 
control element (uCE). The core promoter is located between 
-50 to +20 bp and is essential for basal transcription, whereas 
the uCE is located 150-200 bp upstream of the transcription 
start site and is required for efficient pre-initiation complex 
formation (14) (Fig. 1A). Cooperative binding of the HMG1 
box containing upstream binding factor (uBF) and the selec-
tivity factor (SL1 or TIF-IB) to the promoter region is required 
for Pol I recruitment (15,16). rRNA genes are transcribed as 
long precursors known as 45S pre-RNA which are then rapidly 
spliced into the 18S, 28S and 5.8S rRNA transcripts (17). 
Processed and modified rRNA transcripts are assembled into 
respective ribosomal subunits in the nucleolus (18,19).
The association between the nucleolus and cancer has long 
been known. Abnormal morphology of the nucleolus in cancer 
cells has drawn the attention of tumor pathologists since 
the 19th century. However, only recently has the molecular 
biology of rRNA synthesis and ribosome biogenesis in cancer 
cells begun to be explored.
CpG island methylation at the promoters of tumor 
suppressor genes is known to be an important factor in the 
formation and progression of many types of cancer (20). The 
promoter and transcribed regions of rRNA genes are rich in 
CG dinucleotide yet they are longer than regular 1 to 2 kb CpG 
islands (21). A limited number of studies analyzing the DNA 
methylation status of the rDNA promoter region in cancer have 
focused on the relationship between rDNA promoter methyla-
tion and the expression levels of rRNA genes.
Methylation at the 45S rDNA promoter region decreased 
the expression of rRNA genes in hepatocellular carci-
noma (22) and in CD34+ cells of patients with myelodysplastic 
syndromes (23). On the other hand, other studies have shown 
no relationship or a positive correlation between promoter 
methylation and rRNA transcription (24,25).
Although rRNA genes and particularly 18S RNA are 
frequently used in qRT-PCR as housekeeping genes, recent 
studies have shown that 18S is differentially expressed in breast 
tumor and normal samples (26-28). Furthermore, changes in 
the relative amount of spliced rRNA products from 45S have 
not been tested in the context of breast cancer.
CpG methylation of rDNA has been identified as a prog-
nostic factor in ovarian, endometrial and breast cancer (29-31). 
A recent study also revealed that the 45S rDNA promoter as 
well as the 5' regions of 18S and 28S rDNA are hypermeth-
ylated in breast cancer tissues compared to paired normal 
tissues. Notably, methylation levels of these regions exhibited 
a correlation with nuclear grade and nuclear size values (32). 
However, none of the previous breast cancer studies examined 
the ratio of rRNA transcript levels and rDNA promoter meth-
ylation levels in tumors and normal tissues comparatively.
In the present study, we analyzed the methylation levels of 
the 45S rDNA promoter in breast cancer cell lines as well as 
in primary breast tumor tissues and matched normal samples. 
We also determined the expression levels of rRNA transcripts 
in the same samples in order to understand the role of rDNA 
promoter methylation on rRNA gene expression in breast 
cancer. We showed for the first time that the relative expression 
ratio of 18S and 5.8S rRNA was differentially modulated in 
tumors in comparison to adjacent normal tissues. In addition, 
relative rRNA expression in normal tissues was significantly 
and negatively correlated with the methylation status but this 
was not observed in the breast tumors. Furthermore, the high 
correlation between expression of rRNA transcripts in normal 
breast tissue was lost in tumors. Our findings suggest a signifi-
cant dysregulation of relative rRNA expression in conjunction 
with promoter methylation.
Materials and methods
Cell culture, 5-aza-2'-deoxycytidine (5-AZA) and trichostatin A 
(TSA) treatments. MCF7, MDA-MB-453, MDA-MB-468, 
BT20, MDA-MB-231 and CAMA-1 breast cancer cell lines 
were grown in 10% fetal bovine serum (FBS) (HyClone, 
Thermo Scientific, uSA) and 1% penicillin/streptomycin (P/S) 
supplemented with low glucose Dulbecco's modified Eagle's 
medium (DMEM) (both from HyClone). zR-75-1 cell line was 
grown in 10% FBS, 1% P/S and 2 mM glucose (Sigma-Aldrich, 
uSA) supplemented with RPMI-1640 medium (HyClone). 
BT-474 cell line was propagated in 10% FBS, 1% P/S and 10 µg/
ml insulin (Sigma-Aldrich) supplemented with low glucose 
DMEM. MDA-MB-157 and MDA-MB-361 cell lines were 
grown in 10% FBS, 1 mM sodium pyruvate (Gibco, Invitrogen, 
uSA) and 1% P/S supplemented with low glucose DMEM. 
HCC-1937 cell line was propagated in 10% FBS, 1% P/S and 
1 mM sodium pyruvate supplemented with RPMI-1640 medium. 
MCF10A was grown in 10% FBS, 1% P/S, 10 µg/ml insulin, 
20 ng/ml EGF and 0.5 mg/ml hydrocortisone (both from Sigma-
Aldrich) supplemented with DMEM/Ham's F-12 (1:1) medium 
(Biochrome, Merck Millipore, Germany). SKBR-3 cell line was 
grown in 10% FBS and 1% P/S supplemented with McCoy's 5A 
medium (HyClone). CAL-51 cell line was propagated in 20% 
FBS and 1% P/S supplemented with high glucose medium. All 
cells were grown in 5% CO2 and 95% air at 37˚C in a cell culture 
incubator. All cell lines except MCF-10A and CAL-51 cells were 
purchased from the American Type Culture Collection (ATCC; 
Rockville, MD, uSA). MCF-10A and CAL-51 were kindly 
provided by Assistant Professor Dr A. Elif Erson (Middle East 
Technical university). Short tandem repeat profiling was used to 
verify the authenticity of all cell lines.
A total of 10 breast cancer cell lines (MCF7, MDA-MB-
231, MDA-MB-453, MDA-MB-468, BT-474, zR-75-1, BT-20, 
MDA-MD-361, SKBR-3 and CAL-51) and one non-tumor-
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igenic breast cell line (MCF-10A) were treated with 5-AzA 
or TSA. Cells seeded at a density of 750,000/100 mm were 
treated with either 5 µM 5-AzA (Sigma-Aldrich) or dimethyl 
sulfoxide (DMSO) (same amount used to solubilize 5-AzA). 
Drugs were changed every day along with the medium, and 
cells were collected on day 5. 400 nM TSA or DMSO (same 
amount used to solubilize TSA) was administered to the cells 
24 h after cell plating, and the cells were collected after 48 h.
A total of 10 cell lines (MCF7, MDA-MB-231, MDA-MB- 
453, MDA-MB-468, BT-474, zR-75-1, BT-20, SKBR-3, 
CAL-51 and MCF-10A) were treated with both 5-AzA and 
TSA (combination treatment). 5-AzA (5 µM) was added at 
the day of seeding and 400 nM TSA was added 72 h later in 
combination treatment (5-AzA+TSA); the cells were collected 
on day 5.
Patients and tissue samples. Primary breast tumors and 
matched normal tissues were obtained from 19 patients at 
Ankara Numune Research and Teaching Hospital (Table I). 
Clinical tissue samples were used with the approval of the 
Research Ethics Committee of Ankara Numune Research and 
Teaching Hospital, and consent was obtained from the patients 
according to the Helsinki Declaration.
Tissues acquired from patients during surgery were 
immediately frozen with liquid nitrogen and stored at -80˚C 
until RNA or DNA extraction was performed. Pathological 
examinations were carried out with hematoxylin and eosin 
staining. Only the tumor samples identified by pathological 
examination consisting of >80-90% tumor cells were included 
in the present study.
DNA extraction and bisulfite treatment. Genomic DNA was 
extracted from the breast cancer cell lines as well as the clin-
ical breast cancer and matched normal tissue samples using 
the NucleoSpin Tissue DNA extraction kit (Macherey-Nagel, 
Germany) following the manufacturer's instructions.
Sodium bisulfite treatment of DNA, which converts unme-
thylated cytosine residues to uracil leaving methylated cytosine 
residues unaffected, was performed with 1 µg genomic DNA 
using the EpiTect Bisulfite kit (Qiagen, Germany). Elution was 
performed using 20 µl of elution buffer.
Bisulfite-specific PCR, gel extraction and bisulfite genomic 
sequencing. Bisulfite-converted DNA (1 µl) was amplified 
with Taq DNA polymerase (Fermentas, Thermo Scientific, 
uSA) using bisulfite DNA-specific primers (22) targeting the 
45S rDNA promoter (45S bisulfite sequencing forward and 
reverse primer sequences are listed in Table II). PCR products 
were extracted from the gel using the QIAquick Gel Extraction 
kit (Qiagen). Purified products were cloned into the pGEM-T 
Easy Vector using the pGEM-T Easy Vector system (Promega, 
uSA). The transformation protocol was performed according 
to the pGEM-T Easy Vector system manual using competent 
E. coli DH5α. Bacteria were plated on LB-agar containing 
ampicillin (AppliChem, Germany), IPTG and X-Gal (both 
from Fermentas) and positive clones (five colonies from cell 
lines and 10 colonies from tissue samples) were randomly 
selected.
Small-scale isolation of plasmid DNA (mini-prep) 
was performed with the NucleoSpin Plasmid Isolation kit 
(Macherey-Nagel) according to the manufacturer's instruc-
tions. Plasmids containing the cloned inserts were confirmed 
with PCR using T7 and SP6 universal primers. The insert-
containing plasmids were sequenced with SP6 primers using 
the dideoxy chain-termination method (Iontek, Turkey).
Methylation analysis. Raw bisulfite sequencing data were 
analyzed using the Quantification tool for Methylation 
Analysis) (QuMA), a web-based quantification tool for 
methylation analysis (http://quma.cdb.riken.jp) (33). Bisulfite 
conversion rates of raw sequencing data were determined 
by analyzing unconverted cytosine residues in non-CG sites. 
Clones with a bisulfite conversion rate of <95% were excluded. 
Clones from each sample were trimmed, aligned and displayed 
as lollipop graphs using QuMA.
RNA isolat ion and cDNA synthesis.  The f rozen 
tumor (4-5 slices for each sample) and normal (20-25 slices 
for each sample) tissue samples were cut into 60-µm sections 
and used for RNA isolation. Tissue samples were lysed in 
1 ml TRI reagent RT (Molecular Research Center, uSA) with 
a homogenizer and passed through a 21-gauge needle several 
times. After a 5-min incubation at room temperature, 50 µl of 
4-bromoanisole (Molecular Research Center) was added/ml of 
TRI reagent. Tubes were vortexed for 15 sec and incubated at 
room temperature for 2-3 min. After incubation, the mixture 
was centrifuged at 12,000 x g for 15 min at 4˚C and then the 
aqueous phase was collected into a clean tube. Isopropanol 
(0.5 ml) was added to the aqueous phase/1 ml of TRI reagent 
used. The mixture was incubated at room temperature for 
10 min and then centrifuged at 12,000 x g for 15 min at 4˚C 
to recover the RNA. The supernatant was removed, and the 
pellet was washed with 75% ethanol twice and centrifuged 
at 7,500 x g for 5 min at 4˚C. The pellet was air-dried and 
dissolved in diethylpyrocarbonate (DEPC)-treated H2O. In 
order to avoid DNA contamination of the total RNA acquired 
from the tissue samples, DNase I treatment was performed 
with the Message Clean kit (GenHunter, uSA) according to 
the manufacturer's instructions. Total RNA (500 ng) was used 
in random primed cDNA synthesis with the RevertAid First 
Strand cDNA Synthesis kit (Fermentas).
RNA isolation from the cell lines was performed using 
the NucleoSpin RNA II RNA isolation kit (Macharey-Nagel) 
following the manufacturer's protocol. Total RNA (1 µg) was 
used in random primed cDNA synthesis with the RevertAid 
First Strand cDNA Synthesis kit.
Real-time PCR. Real-time PCR was performed with primers 
targeting 45S ETS, 18S, 28S and 5.8 rRNA transcripts. All 
primer sequences are listed in Table II. Randomly primed 
cDNAs from both cell lines and frozen tissue samples were 
diluted in a 1/5 ratio. Diluted cDNA (1 µl) was used in every 
reaction containing 10 µl of DyNAmo SYBR-Green qPCR 
kit (Thermo Scientific) and 10 pmol of forward and reverse 
primers in a final volume of 20 µl. Thermal cycling condi-
tions were as follows: initial denaturation for 5 min at 95˚C, 
40 cycles of 30 sec at 95˚C, 30 sec at 60˚C and 30 sec at 72˚C 
followed by melting curve. All reactions were set as duplicates. 
The Stratagene Mx3005P Real-Time PCR System (Agilent, 
uSA) was used for real-time PCR experiments.
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The relative expression levels of rRNAs were evaluated 
using log2 (2ΔCt) calculation. TBP was used as the reference 
gene both for cell lines and clinical tissue samples to assess 
the amount of cDNA. The geometric mean of the rRNA 
expression values (GM-rRNAs) (18S, 28S, 5.8S and 45S ETS) 
was also used as a reference gene in tissue samples in order 
to understand the relative changes of rRNAs with respect to 
each other.
Statistical analysis. Raw bisulfite sequencing data were 
aligned, trimmed and quality checked using QuMA. Lollipop 
graphs and pie charts of the methylation status were also gener-
ated using QuMA (33). The Wilcoxon matched pairs signed 
rank test was used to assess both sample-wise and CpG-wise 
significant methylation differences between breast tumor and 
matched normal samples. Significant expression differences 
were determined using the paired t-test. Correlations between 
45S rDNA promoter methylation and rRNA expression levels, 
as well as rRNA transcripts with each other were analyzed 
using Spearman correlation.
The association of rDNA promoter methylation and 
rRNA expression with clinical variables was evaluated with 
Spearman correlation. p<0.05 was accepted as statistically 
significant for all statistical analyses. All statistical analyses 
of methylation and expression data were performed using IBM 
SPSS software version 21.0 or GraphPad Prism 6.0.
Results
45S rDNA promoter is highly methylated in breast cancer 
cell lines. To identify the methylation levels of the 45S rDNA 
promoter region in breast cancer in vitro, we performed 
bisulfite genomic sequencing for the 45S rDNA promoter 
region in 10 breast cancer cell lines and a non-tumorigenic 
breast cell line (MCF-10A). Bisulfite sequencing primers 
were obtained from a previous study (22), which amplified 
a 434-bp region spanning two important elements: uCE and 
the core promoter (34) (Fig. 1B). Isolated DNAs from the cell 
lines were treated with sodium bisulfite reagent, allowing 
for integration of epigenetic information (DNA methylation) 
into genetic information. Five randomly selected clones from 
each cell line were sequenced, aligned and analyzed using 
QuMA (33). All cell lines, including a non-tumorigenic breast 
cell line, MCF-10A, exhibited very high levels of methylation 
(varying between 74 and 96%) in their 45S rDNA promoter 
regions (Fig. 2).
Breast tumors are heavily methylated compared to their 
normal matched tissues in the 45S rDNA promoter region. 
We analyzed 19 breast tumor and matched normal frozen 
tissues (Table I) using the same bisulfite genomic sequencing 
method to test whether methylation levels of the 45S rDNA 
promoter region in patient samples were similar to those of 
the cell lines. Ten randomly selected clones were sequenced, 
Figure 1. The human rDNA promoter. (A) Structural organization of human rDNA repeating unit. Bisulfite sequencing primers are shown by inward 
pointing arrows. IGS, intergenic spacer; uCE, upstream control element; CP, core promoter; ETS, external transcribed spacer; ITS, internal transcribed 
spacer. (B) Sequence of the amplified PCR product, spanning the upstream core element (marked with dashed line) and the core promoter (straight line). There 
are 54 CpGs in the 434-bp region analyzed; the transcription start site is indicated with a curved arrow. Primers are shown with italicized characters and 
CG-dinucleotides are indicated with bold characters. rDNA, ribosomal DNA.
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aligned and analyzed from each of the breast tumor and 
normal pairs using QuMA (33). We used the Wilcoxon signed 
rank test for testing the paired differences instead of the 
Mann-Whitney u test offered by the QuMA tool. Our results 
revealed that 13 out of 19 (68%) breast cancer tissue samples 
had higher methylation levels of the 45S rDNA. On the other 
hand, three samples showed significantly higher methyla-
tion levels in normal samples compared to their tumor pairs, 
whereas there was no significant difference between promoter 
methylation levels in breast tumor and matched normal tissues 
Table I. Clinicopathological characteristics of the patients.
Patient Age    Path  Clinical  -DM
no. (years) ER PR Diagnosis lymph node Grade grade DM month
113 63 + - IDC + 1 Grade 3B + 20
115 57   Papillary carcinoma - 3 Grade 2A - 
  96 39 - + IDC - 2 Grade 2A - 
116 74 - - IDC + 2 Grade 2A - 
137 42 - + Medullary - 3 Grade 2B - 
146 49 + + ILC +  Grade 2B - 
148 70 + - IDC + 2 Grade 3A + 15
154 32 - - IDC + 3 Grade 3B - 
159 30 - + Metaplastic - 2 Grade 2A - 
161 41 - - IDC - 2 Grade 2B + 47
164 74 + + IDC - 2 Grade 2B - 
166 55 - + IDC + 2 Grade 2A - 
168 44 - + IDC + 2 Grade 2B - 
170 60 - - IDC + 2 Grade 3B - 
176 49 + + IDC + 2 Grade 2A - 
177 47 - + IDC + 2 Grade 3A + 48
181 44 - - IDC + 2 Grade 1 - 
133a         
173a         
aPatients with missing information. ER, estrogen receptor status; PR, progesterone receptor status; IDC, infiltrating ductal carcinoma; Path 
lymph node, pathological lymph node status; DM, distant metastasis status.
Table II. Primers used in the present study.
   Product size Efficiency
Primer Sequence (bp) value
45S bisulfite sequencing primers Forward 5'-GAGTCGGAGAGCGCTCCCTGAG-3' 434 -
45S bisulfite sequencing primers Reverse 5'-CTGGAGAGGTTGGGCCTCCG-3'
18S rRNA Forward 5'-AAACGGCTACCACATCCAAG-3' 154 1.95
18S rRNA Reverse 5'-CCTCCAATGGATCCTCGTTA-3'
28S rRNA Forward 5'-CAGGGGAATCCGACTGTTTA-3' 151 1.85
28SS rRNA Reverse 5'-ATGACGAGGCATTTGGCTAC-3'
5.8S rRNA Forward 5'-CTCTTAGCGGTGGATCACTC-3' 155 2.00
5.8S rRNA Reverse 5'-GACGCTCAGACAGGCGTAG-3'
45S ETS Forward 5'-CGATCTGAGAGGCGTGCCTT-3' 87 1.93
45S ETS Reverse 5'-GGCAGCGCTACCATAACGGA-3'
TBP Forward 5'-TGCACAGGAGCCAAGAGTGAAAT-3' 134 2.20
TBP Reverse 5'-CACATCACAGCTCCCCACCA-3'
rRNA, ribosomal RNA; ETS, external transcribed spacer.
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in the remaining three samples (Fig. 3A). Normal samples were 
not fully unmethylated and instead showed a mosaic meth-
ylation pattern, a relatively common observation for human 
rDNA promoters (22). Methylation patterns of tumor and 
normal pairs showed a significant correlation with each other. 
To test whether this correlation was due to patient-specific 
methylation of rDNA promoters, we performed a correla-
tion analysis between randomly selected tumor and normal 
samples; and these showed similar degrees of correlation (data 
not shown). In addition, the analysis of individual CpGs in 
tumor and normal pairs revealed significant methylation levels 
in different CpGs identified with the Wilcoxon matched pairs 
signed rank test (Fig. 3B).
No significant correlation was identified between rDNA 
promoter methylation levels and patient clinical variables.
Expression levels of rRNA transcripts in breast cancer. TBP, 
GAPDH and ACTB have been used as reference genes to 
determine rRNA expression levels in several studies (23,24,35) 
but these RNA polymerase II (Pol II) transcribed genes are 
variably expressed in numerous types of cancer (36,37). 
However, several studies advise against using rRNA levels to 
determine mRNA levels (26,27). Accordingly, using mRNA 
levels to normalize rRNA levels may have a similar drawback. 
Herein, we propose that GM-rRNA, the geometric mean of 
expression from an rRNA pool (18S, 28S, 5.8S and 45S ETS) 
Figure 2. The methylation status of the 45S rDNA promoter in breast cancer cell lines and a non-tumorigenic cell line. A total of 54 CpGs in a region spanning 
-381 to +53 bp was analyzed by the bisulfite sequencing method. Each row corresponds to the sequence analysis of one clone and each column represents the 
CpG positions. The filled and empty circles stand for methylated and unmethylated CpGs, respectively. Average methylation percentages of the clones for each 
sample are indicated at the right of the graph. uCE, upstream control element.
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synthesized by Pol I, can be used to analyze relative changes in 
rRNAs with respect to each other between tumor and normal 
samples, as well as in cell lines. We performed our analyses 
using both TBP and GM-rRNA normalization to test the effect 
of normalization on expression changes in rRNA transcripts.
Expression of rRNA transcripts is highly variable in breast 
cancer cell lines. It is known that promoter DNA methylation 
has a repressive effect, particularly on Pol II transcribed 
genes in cancer (20,38) and increased methylation levels are 
implicated in decreased levels of rRNA transcription (22,23). 
Thus, we hypothesized that rRNA transcription levels may 
also be downregulated in these breast cancer cell lines with a 
hypermethylated 45S rDNA promoter. Total RNA was isolated 
and tested in cell lines with qRT-PCR using primers targeting 
Figure 3. Methylation status of the 45S rDNA promoter region in clinical breast cancer and matched normal tissues. (A) The methylation status of each CpG 
dinucleotide in the region spanning -381 to +53 bp was analyzed in 19 breast cancer and normal pairs. Ten randomly selected clones were sequenced from each 
sample. Significant (**p<0.0001 and *p<0.05) methylation difference between tumor and matched normal samples. (B) Methylation levels of every CpG in all 
tumor clones and normal clones were compared to determine differentially methylated CpGs. Methylation percentages of every CpG are presented as a pie 
chart. Significantly (*p<0.05) methylated CpGs in tumor samples compared to normal samples.
Figure 4. rRNA transcript levels in breast cancer cell lines (A) Relative expression levels of rRNA transcripts in the breast cancer cell line panel, normalized 
to the TBP transcript level. (B) Relative proportions of rRNA transcripts in the breast cancer cell line panel, normalized to GM-rRNA.
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Pol I products 18S, 28S, 5.8S and 45S external transcribed 
spacer (ETS) region.
All of the rRNA transcripts were expressed at varying 
levels among the cell lines when normalization was performed 
with the TBP gene (Fig. 4A). Similar results were obtained 
when we used GM-rRNA to determine changes in the ratio of 
the rRNA transcripts (Fig. 4B).
Epigenetic drugs 5-AZA and 5-AZA+TSA modulate 
expression of rRNA transcripts. To further establish the 
relationship between 45S rDNA promoter methylation and 
rRNA expression, we used the hypomethylating agent, 
5-AzA, which prevents DNA methylation by inhibiting DNA 
methyltransferases (39) and leads to increased RNA transcription. 
TBP normalized expression levels of 5.8S and 45S ETS transcripts 
were significantly decreased upon 5-AzA treatment (Fig. 5A). 
However, proportion of rRNA transcripts did not exhibit 
significant differences between 5-AzA- and DMSO-treated 
samples (normalization with GM-rRNA) (Fig. 5B).
TSA is a non-specific histone deacetylase (HDAC) inhib-
itor. TSA treatment of cells affects the acetylation status of 
Figure 5. rRNA transcript levels in 5-AzA- and DMSO (control)-treated cell lines. (A) Expression levels of rRNA transcripts in 5-AzA- or DMSO-treated 
breast cell lines. Expression levels of rRNA transcripts were normalized to the TBP transcript level. (B) Relative proportions of rRNA transcripts in the 
5-AzA- or DMSO-treated breast cell lines. Expression levels of rRNA transcripts were normalized to GM-rRNA. Box plots indicate relative expression levels 
of rRNA transcripts in the DMSO- and 5-AzA-treated cell lines. Significant (*p<0.05) rRNA expression differences between DMSO- and 5-AzA-treated 
cell lines were determined using the paired t-test. rRNA, ribosomal RNA; 5-AzA, 5-aza-2'-deoxycytidine; DMSO, dimethyl sulfoxide; GM-rRNA, geometric 
mean of rRNA expression values.
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H3 and H4 and thus TSA indirectly upregulates gene expres-
sion by dispersion of the chromatin structure (39). Therefore, 
TSA was used to determine whether other mechanisms (such 
as histone acetylation) are involved in the rRNA synthesis 
besides DNA methylation. TSA treatment alone did not 
significantly alter the expression levels or the relative propor-
tions of the rRNA transcripts when normalized with TBP or 
GM-rRNA, respectively (data not shown). Treatment with 
5-AzA and TSA together (5-AzA+TSA) did not significantly 
affect the TBP normalized expression levels of the rRNA tran-
scripts (Fig. 6A). However, the 5.8S proportion of rRNAs was 
significantly decreased in the 5-AzA+TSA-treated samples 
compared to the DMSO-treated samples (Fig. 6B).
Relative expression levels of 18S and 5.8S transcripts are 
altered in breast tumors. Next, we tested whether increased 
levels of methylation of the 45S rDNA promoter in tumor 
Figure 6. rRNA transcript levels in the 5-AzA+TSA- and DMSO (control)-treated cell lines. (A) Expression levels of rRNA transcripts in the 5-AzA+TSA- 
or DMSO-treated breast cell lines. Expression levels of rRNA transcripts were normalized to the TBP transcript level. (B) Relative proportions of rRNA 
transcripts in the 5-AzA+TSA- or DMSO-treated breast cell lines. Expression levels of rRNA transcripts were normalized to GM-rRNA. Box plots indicate 
relative expression levels of rRNA transcripts in the DMSO- and 5-AzA+TSA-treated cell lines. Significant (*p<0.05) rRNA expression differences between 
DMSO- and 5-AzA+TSA-treated cell lines were determined using the paired t-test. rRNA, ribosomal RNA; 5-AzA, 5-aza-2'-deoxycytidine; TSA, tricho-
statin A; DMSO, dimethyl sulfoxide; GM-rRNA, geometric mean of the rRNA expression values.
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samples led to repressed expression levels of rRNA transcripts. 
RNA isolation was performed from the same tissue samples 
used in the methylation analysis (only 14 of 19 paired tissue 
samples had enough tissue for RNA isolation). Expression 
levels, when analyzed using TBP as a reference gene, did not 
differ between the tumors and corresponding adjacent normal 
tissues for any of the rRNA transcripts (Fig. 7A). However, 
when normalized with GM-rRNA, the proportion of 18S was 
significantly decreased in the tumor samples whereas that of 
5.8S rRNA was significantly increased (Fig. 7B).
rRNA transcripts are expressed independent from 45S rDNA 
promoter methylation levels in breast cancer cell lines. There 
was no significant correlation of rDNA methylation levels with 
rRNA expression levels or rRNA ratios in the breast cancer 
cell lines or in the MCF10A cells (non-tumorigenic cell line). 
Figure 7. Expression analysis of rRNA transcripts in clinical breast cancer and normal pairs. Relative expression levels of rRNA transcripts are shown with 
box plots for the clinical breast cancer and matched normal samples. (A) Expression levels of rRNA transcripts were normalized to the TBP transcript 
level. (B) Expression levels of rRNA transcripts were normalized to GM-rRNA. Significant (*p<0.05) expression differences between normal and tumor 
samples were determined using paired t-test. rRNA, ribosomal RNA; GM-rRNA, geometric mean of the rRNA expression values.
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rRNA expression levels, as well as relative rRNA proportions 
in cell lines were found to be independent of their promoter 
methylation levels (data not shown). These results indicate 
that rRNA transcripts were expressed even in the presence of 
heavy methylation at the 45S rDNA promoter.
Correlation between 45S rDNA promoter methylation 
and 18S rRNA expression is disrupted in breast tumors. Next, 
Spearman's correlation analysis was performed to test whether 
the 45S rDNA promoter methylation levels in the breast tumor 
and matched normal samples were correlated with either rRNA 
expression levels or rRNA proportions in the rRNA pool. 
When rRNA expression levels were normalized with TBP 
expression, no correlation between expression and methylation 
was observed (data not shown). The increase in methylation 
of the rDNA promoter levels in the normal samples was 
inversely correlated with the 18S rRNA/GM-rRNA expres-
sion ratio (Spearman r=-0.6571 and p=0.0128), yet promoter 
hypermethylation did not exhibit any correlation with 18S 
rRNA/GM-rRNA ratios in the tumor samples (Fig. 8).
Furthermore, Ct values of rRNAs transcribed from the 
45S rDNA promoter were highly correlated with each other in 
the normal samples, yet this correlation was lost in the tumor 
samples (Table III).
rRNA expression levels were correlated with the grade of 
breast cancer. Expression of the 45S ETS region (TBP normal-
ization) in tumor samples (n=11) was positively correlated 
with the grade of breast cancer (Spearman r=0.650, p=0.03). 
Additionally, the 28S/GM-rRNA ratio of tumor samples was 
also positively correlated (Spearman r=0.725, p=0.012) while 
the 18S/GM-rRNA ratio was negatively correlated with the 
grade (Spearman r=-0.714, p=0.014).
Discussion
A high expression of rRNA transcripts characterizes cancer 
cells but only a few studies have analyzed the expression of 18S 
rRNA in breast cancer tissues and matched normal samples. 
Previous studies have mostly focused on testing whether 
rRNA genes are suitable as reference genes (26,27). One of 
these studies found that 18S rRNA was expressed at lower 
levels in breast tumors compared to matched normal tissues in 
contrast to the general acceptance of higher rRNA expression 
in tumors (26). None of the studies, however, investigated 
whether the expression difference between breast cancer 
and normal pairs was due to rDNA promoter methylation or 
whether the ratios of spliced products of the 45S precursor 
were differentially expressed between tumor and normal pairs 
in breast cancer.
DNA methylation is a well-known phenomenon that inac-
tivates transcription by interfering with Pol II binding to the 
Table III. Correlation analysis between rRNA transcripts in tumor and normal samples.
Sample Transcript 28S rRNA 5.8S rRNA 45S ETS
Normal 18S rRNA 0.837 (p<0.01)a 0.824 (p<0.01)a 0.818 (p<0.01)a
 28S rRNA  0.833 (p<0.01)a 0.674 (p=0.012)a
 5.8S rRNA   0.57 (p=0.033)a
Tumor 18S rRNA 0.042 (p=0.887) -0.051 (p=0864) 0.288 (p=0.318)
 28S rRNA  0.521 (p=0.056) 0.349 (p=0.221)
 5.8S rRNA   0.543 (p=0.045)a
Significant correlation (ap<0.05) was identified using Spearman correlation coefficients (r) and p-values. rRNA, ribosomal RNA; ETS, external 
transcribed spacer.
Figure 8. Correlation graph of 45S rDNA promoter methylation levels and 18S rRNA ratios in breast tumor and matched normal tissue samples. A significant 
correlation (*p<0.05) was identified using Spearman correlation analysis.
KARAHAN et al:  DYSREGuLATION OF rDNA PROMOTER METHYLATION AND rRNA IN BREAST CANCER3142
promoter (40); since Pol I and Pol II share common features 
and transcription factors (41-43), DNA methylation in the 45S 
rDNA promoter may have a similar effect on expression of 
rRNA genes.
We used both breast cancer cell lines and clinical breast 
cancer tissues to investigate the methylation levels of rDNA 
promoters and expression differences of rRNA transcripts, 
as well as their relationship with each other in breast cancer. 
We found that breast cancer cell lines were hypermethyl-
ated (74-96% methylation) at the 45S rDNA promoter 
region (Fig. 2). High methylation levels of rDNA promoters are 
frequently identified in many transformed cell lines such as 
Jurkat, CEM, HeLa, KB (44), NIH 3T3 (45) and HEK293 (46). 
A genome-wide analysis of aberrant methylation changes with 
aging in mammals identified the rDNA gene locus in which 
methylation levels increased age-dependently in both sperma-
tozoa and rat liver cells (47). If the rDNA locus is sensitive to 
accumulating random methylation over time, the high methyla-
tion levels found in breast cancer cell lines may be explained 
with long-continued culturing, a common characteristic of 
cancer cell lines.
We could not identify two populations of alleles (one popu-
lation with a hypermethylated promoter, the other population 
with a hypomethylated promoter; Fig. 2) in breast cancer cell 
lines as proposed earlier by other studies (22-25). Considering 
the repetitive nature of rRNA genes, this result may be due 
to the low number of clones (5 clones) analyzed for each 
cell line. Breast cancer cell lines with hypermethylated 45S 
rDNA promoters did not repress or alter the ratio of rRNA 
transcripts (Fig. 4). rRNA expression levels and proportions of 
rRNA transcripts were found to be independent of the rDNA 
promoter methylation levels; this result may indicate that the 
methylation of the 45S rDNA promoter may not be solely 
responsible for rRNA expression or proportion changes in 
breast cancer cell lines. Completely methylated (Xenopus leavis 
sperm DNA) and unmethylated rDNA constructs were found 
to be transcribed with equal efficiency when transfected to 
Xenopus leavis oocytes (48). This is consistent with our results 
in which expression of rRNA transcripts was found to be rela-
tively independent of their rDNA promoter methylation levels.
upon 5-AzA treatment of breast cancer cell lines, expression 
of some forms of mature rRNA transcripts (significant 
for 5.8S RNA and 45S ETS) unexpectedly decreased 
compared to the DMSO-treated group when normalized with 
TBP (Fig. 5A), while rRNA proportions were not significantly 
altered within the rRNA pool (Fig. 5B). A recent study 
demonstrated that the loss of CpG methylation of the rDNA 
promoter (either with 5-AzA treatment or DNMT knockout) 
regions caused cryptic transcription of RNA polymerase II 
from 45S rDNA promoters. Cryptic transcription from rDNA 
promoters by RNA polymerase II significantly correlates with 
reduced modification and processing of rRNA transcripts (25). 
Loss of CpG methylation at rDNA promoter regions in 
5-AzA-treated breast cancer cell lines may be affected by 
this cryptic RNA polymerase II transcription, which explains 
the downregulation of 5.8S and 45S ETS rRNA transcripts 
in the 5-AzA-treated cell lines. This mechanism, which acts 
as a negative feedback loop, may be a strategy developed by 
cells to achieve a balanced expression of rRNA transcripts and 
prevent energy loss in cells in the absence of CpG methylation.
Gene expression is usually regulated by a combination of 
DNA methylation, histone modifications and the activities of 
chromatin remodeling complexes (49). TSA treatment alone 
and 5-AzA+TSA treatment did not result in a significant 
increase in rRNA levels (Fig. 6A), yet the 5.8S rRNA ratio 
was decreased in the 5-AzA+TSA treated group (Fig. 6B). 
rRNA transcription may predominantly be regulated by other 
transcriptional or post-transcriptional mechanisms rather than 
epigenetic regulatory processes (at least DNA methylation and 
histone acetylation) in breast cancer cell lines.
The discrepancy between rRNA expression levels (TBP 
normalization) and rRNA ratios (GM-rRNAs) in the 5-AzA- 
and 5-AzA+TSA-treated groups, compared to their controls, 
may result from expression changes of TBP upon drug treat-
ment. The change may also be due to some indirect effect of 
the drugs through other genes as both drugs affect several 
other genes along with the rDNA genes.
Further analysis of rDNA promoter methylation with the 
Wilcoxon matched-pairs signed rank test in tissues showed 
that most of the breast tumors (13/19) had significantly higher 
methylation levels than their normal counterparts (Fig. 3A). 
Our findings indicated similarities of methylation patterns 
within tumors and between tumor and adjacent normal tissues, 
indicating tissue- and/or locus-specificity of methylation. 
Methylation analysis of the same region in different tissues and 
types of cancer may reveal whether the methylation pattern of 
this region is tissue-specific, cancer-specific or neither, since 
different tissues display different methylation patterns at 
different loci (50).
Previous studies have identified rDNA methylation as a 
prognostic factor in some cancer types (31,51) including breast 
cancer (30). However, the correlation analysis of methylation 
levels with clinicopathological characteristics (as described in 
Table I) of the patients used in the present study did not show 
any significance (data not shown). Similarly, a breast carcinoma 
study on 45 paired breast tumor and normal samples could 
not identify any significant associations between methylation 
of rDNA promoters, 5' regions of 18S and 28S rDNA and 
ER, PR, grade and other clinicopathological features, except 
nuclear size and grade (32). The use of larger sample sizes 
may help clarify the clinical importance of rDNA methylation 
in breast cancer. rRNA transcript expression (45S/TBP and 
28S/GM-rRNA) in tumors on the other hand showed a positive 
correlation with the grade of the tumor. Nuclear pleomorphism 
is one of the criteria used in the grading of breast cancer, which 
includes classification of tumors by the size and the shape of 
the nucleoli (52). An increase in the expression or the ratio of 
rRNA transcripts may be responsible for the abnormal appear-
ance of nucleoli in higher grade breast cancer samples.
Expression analyses of rRNA transcripts with TBP and 
GM-rRNA normalizations revealed different sides of the same 
coin. While the former enables measurement of expression 
with respect to a stable mRNA pool, use of the latter reflects 
changes in the relative ratios of rRNA transcript levels. Our 
data accordingly revealed that 5.8S and 45S rRNA transcripts 
were downregulated in the 5-AzA-treated cell lines with TBP 
normalization (Fig. 5A). However, 5-AzA treatment did not 
affect rRNA ratios in the cell lines (Fig. 5B). unlike the cell 
line results, expression analysis of rRNA genes in the breast 
tumor and matched normal tissues showed no significant 
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difference when normalized with TBP (Fig. 7A) while 18S 
and 5.8S rRNAs were proportionally altered in the breast 
tumor tissue samples (Fig. 7B). As stated earlier, the disparity 
between TBP and GM-rRNA normalizations could be due to 
the fact that they analyze separate aspects of rRNA expression.
A recent study with results supporting our findings demon-
strated that two rRNA forms (5.8S and 45S precursors) were 
overexpressed (TBP normalization) in clinical prostate cancer 
tissues compared to matched-benign tissues. However, meth-
ylation levels of the 45S rDNA promoter in the same prostate 
tumor and normal pairs were not significantly different (24). 
Another study showed that loss of CpG methylation at the 
rDNA promoter surprisingly decrease rRNA transcript levels 
by disrupting rRNA synthesis and processing via activating 
cryptic transcription of rRNA genes by Pol II (25).
Different studies have used various reference genes, TBP 
and ACTB being among the most common, to determine 
rRNA expression levels in cancer (23,24,35). We used TBP (a 
RNA polymerase II transcribed gene) to normalize rRNA 
gene expression and found no significant differences between 
the breast tumor and matched normal samples. ACTB also 
failed to identify such differences in our cohort (data not 
shown). We propose that the geometric mean (GM) of rRNAs 
synthesized by RNA polymerase I (18S, 5.8S, 28S and 45S 
ETS) to normalize rRNA expression can be used to detect 
relative changes in rRNAs with each other. GM-rRNA may 
be less prone to changes than Pol II gene transcripts since it 
is calculated from the rRNA transcripts synthesized by Pol I. 
When GM-rRNA was used for normalization, 5.8S and 18S 
rRNA expression levels were significantly upregulated and 
downregulated, respectively, in the tumor samples compared 
to the normal pairs (Fig. 7B). Our data indicate that the 
proportion of 18S and 5.8S rRNA in the total rRNA pool 
changed in the opposite direction while total rRNA levels 
may be relatively constant. We found that methylation levels 
of normal samples (which exhibit mixed methylation patterns) 
showed a negative correlation with the 18S rRNA/GM-rRNA 
expression level but this correlation was disrupted in the tumor 
samples (Fig. 8). As far as we are aware, this is the first study 
to show that the methylation status may be reflected in the 
expression of one or more rRNA transcripts but not all.
Some forms of polycistronic mRNAs and miRNAs that 
are expressed from the same promoter have been shown to be 
post-transcriptionally regulated and exist at different levels in 
plants (53,54). The SNRPN-SNuRF gene, possessing a biscis-
tronic structure and sharing a common promoter, for example, 
is differentially expressed, as identified by both northern 
blot and microarray analysis in mammalian cells (55,56). As 
reported in other studies, genes that are expressed from the 
same promoter can be differentially expressed by other mech-
anisms apart from the effect of basal transcription machinery.
The maturation of ribosomes is a complex process assisted 
by multiple factors (~200) that need to be orchestrated in 
harmony (57,58). Alteration in the methylation levels of 
rDNA promoters may have an effect on rRNA stabilization, 
which could leads to this non-proportional change in rRNA 
transcripts. Moderate levels of rDNA promoter methylation 
(as observed in normal samples) may still be regulating 18S 
rRNA levels but this correlation is disrupted in tumor samples, 
possibly due to the high methylation levels found in the 
45S rDNA promoter. Another possibility is that methylation 
levels can indirectly affect splicing, post-transcriptional modi-
fications and stabilization of rRNA transcripts (25). The fact 
that normal samples showed a higher correlation between rRNA 
transcript expression while this correlation was disrupted in 
tumor samples supported this possibility (Table III), indicating 
that the methylated promoter of 45S rDNA in tumors may have 
an effect on the processing of rRNAs.
Since rRNA processing and modification are largely depen-
dent on snoRNAs, any change in snoRNA levels globally may 
be reflected in the rRNA ratios. u50 is a box C/D snoRNA that 
is required for 2'-O-methylation of two specific positions in the 
28S rRNA and was shown to be altered by somatic rearrange-
ments, mutations and deletions in prostate cancer (59), breast 
carcinoma (60), B-cell lymphoma (61) and colon cancer (62). 
Another snoRNA, GAS5, was also found to be downregulated 
in breast cancer (63). Increased methylation levels of rDNA 
promoters and their effect on rRNA modification and processing 
need to be better analyzed in future studies.
In conclusion, we found that rRNA transcripts were 
expressed independently of the hypermethylated 45S rDNA 
promoter region in breast cancer cell lines. However, the 
18S rRNA/GM-rRNA ratios were significantly correlated 
with methylation levels in the normal samples but not in the 
tumor samples. Promoter methylation of rDNA promoters 
appears to have a different role than regulating the expres-
sion of rRNA transcripts in breast cancer. It may be used as a 
mechanism to stabilize and protect these essential genes under 
any circumstances. rDNA repeats have been proposed to be 
responsible for genomic stability (64) and hypomethylation 
of rDNA promoter has been implicated in decreased genomic 
stability (65,66). Increased methylation of the rDNA promoter 
in tumor cells may be an indicator of the tumor cell effort to 
restore impaired genomic stability. Future research is needed 
to evaluate the cause of relative expression changes observed 
among rRNA transcripts in tumors and their relationship with 
rDNA promoter methylation.
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